Detalhe da pesquisa
1.
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Nature
; 603(7903): 942-948, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-35322232
2.
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.
Cell
; 150(6): 1107-20, 2012 Sep 14.
Artigo
Inglês
| MEDLINE | ID: mdl-22980975
3.
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
N Engl J Med
; 384(13): 1191-1203, 2021 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33789008
4.
German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer.
Gastric Cancer
; 27(1): 6-18, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37847333
5.
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
Int J Cancer
; 153(1): 153-163, 2023 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36883420
6.
Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer.
Oncologist
; 28(12): e1209-e1218, 2023 Dec 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37597246
7.
The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis.
J Transl Med
; 21(1): 552, 2023 08 17.
Artigo
Inglês
| MEDLINE | ID: mdl-37592303
8.
Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction.
Ann Surg Oncol
; 30(12): 7422-7433, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37210683
9.
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus.
Future Oncol
; 19(11): 739-752, 2023 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-36919706
10.
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Lancet
; 398(10294): 27-40, 2021 07 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34102137
11.
Long-Term Outcome After Histopathological Complete Response with and Without Nodal Metastases Following Multimodal Treatment of Esophageal Cancer.
Ann Surg Oncol
; 2022 Apr 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35403919
12.
[What should specialist in internal medicine be aware of in patients treated with biologics? : Infections and autoimmune phenomena]. / Was muss der Internist bei Patienten unter Biologikabehandlung beachten? : Infektionen und Autoimmunphänomene.
Internist (Berl)
; 63(2): 165-170, 2022 Feb.
Artigo
Alemão
| MEDLINE | ID: mdl-35089363
13.
Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma.
Cancer Immunol Immunother
; 70(4): 893-907, 2021 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-33006650
14.
Optimized PD-L1 scoring of gastric cancer.
Gastric Cancer
; 24(5): 1115-1122, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-33954872
15.
Sex-specific prognostic effect of CD66b-positive tumor-infiltrating neutrophils (TANs) in gastric and esophageal adenocarcinoma.
Gastric Cancer
; 24(6): 1213-1226, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34009535
16.
Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma.
Cancer Immunol Immunother
; 69(4): 523-533, 2020 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-31960110
17.
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Invest New Drugs
; 38(4): 1145-1155, 2020 08.
Artigo
Inglês
| MEDLINE | ID: mdl-31707688
18.
Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas.
BMC Cancer
; 20(1): 587, 2020 Jun 22.
Artigo
Inglês
| MEDLINE | ID: mdl-32571252
19.
Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
BMC Cancer
; 20(1): 12, 2020 Jan 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31906887
20.
Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data.
Gastric Cancer
; 23(4): 627-638, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32107691